AOD-9604: what the human trials found
Reviewed 14 sourcesPublished by PepVault
AOD-9604 in people: six trials, about 900 adults. The best 12-week dose lost 2 kg more than placebo; the 24-week trial found under 1 kg. What that means.

- Last reviewed
- Sources
- 14
- Questions
- 8
- Compounds
- 2
The short answer
AOD-9604 did not deliver meaningful weight loss in people. In its 300-person, 12-week trial the best dose, 1 mg a day by mouth, lost 2.8 kg against 0.8 kg on placebo, a gap that missed significance on the trial's main analysis. The 536-person, 24-week trial that followed found less than 1 kg over placebo at every dose, and its maker stopped obesity development in 2007.
Evidence: Six sponsor-funded, randomized, placebo-controlled trials in 893 adults (2001 to 2006), with efficacy reported only in company announcements; the mechanism comes from mouse and rat studies.

What is AOD-9604?
AOD-9604 is a 16-amino-acid piece of human growth hormone: the hormone's last 15 building blocks, numbers 177 to 191, with one extra tyrosine added at the front to make the peptide more stable111. Its sequence is YLRIVQCRSVEGSCGF1. In natural growth hormone the amino acid at position 176 is a phenylalanine, so the tyrosine sits where 176 would be, and that is why the same peptide is often labelled "fragment 176-191"512. Our comparison of the two names covers that overlap.
The idea came from Frank Ng's lab at Monash University in Melbourne, and Metabolic Pharmaceuticals carried it into human trials as an obesity pill2. The goal was to keep growth hormone's fat-releasing effect, called lipolysis (fat cells breaking down stored fat), and leave out its growth signal, its rise in IGF-1 (the growth factor the liver makes in response to growth hormone) and its effect on blood sugar1.
Peptide SkySee AOD-9604 as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
What did the animal studies show?
In obese mice, the bare 177-191 fragment cut weight gain and fat mass and slowed the making of new fat6. In obese Zucker rats given AOD-9604 by mouth for 19 days, weight gain was less than half the control group's: 15.8 g against 35.6 g, with no harm to insulin sensitivity7. In obese mice given it for 14 days, it raised fat burning and fat breakdown without raising blood sugar, and in cell tests it did not bind the growth hormone receptor or make cells multiply8.
In mice bred without the beta-3 receptor, the main fat-releasing receptor on fat cells, two weeks of treatment changed neither weight nor fat breakdown, so in mice the long-term effect needed that receptor, though AOD-9604 does not act on it directly: a single dose still raised fat burning in those mice9. One more animal result is behind the joint claims: in 32 rabbits with damaged knees, AOD-9604 injected into the joint lowered cartilage damage scores10. Those results set up the human trials below.
Which human trials were run?
Six randomized, double-blind, placebo-controlled trials, all in Australia between 2001 and 2006, with 893 adults in total1. None is on ClinicalTrials.gov; the two large ones were registered with Australia's drug regulator, the TGA1. Every trial gave AOD-9604 by IV drip or as a capsule or tablet. None tested it as an injection under the skin, the way it is used today1.
| Study | Who | Length | What was measured | Result |
|---|---|---|---|---|
| Phase 1, IV1 | 15 healthy men | Single doses, a week apart | Safety, blood sugar, IGF-1 | No change in blood sugar or IGF-1; side effects mild and spread evenly across doses and placebo |
| Phase 2a, IV1 | 23 men with obesity | Single doses, a week apart | Safety, blood sugar, IGF-1 | No change in blood sugar or IGF-1; 5 reported mild or moderate euphoria during AOD-9604 periods |
| Phase 2a, oral1 | 17 men with obesity | Single doses, 2 weeks apart | Safety, IGF-1 | No change in IGF-1; well tolerated overall, with one serious bout of diarrhoea at the top dose judged possibly related |
| Phase 2a, oral1 | 36 men with obesity | 7 days | Safety, glucose tolerance | No change in IGF-1, glucose or insulin; more headache and diarrhoea at the top dose |
| Phase 2b, oral12 | 300 adults, BMI 35 or more | 12 weeks | Weight loss | Best dose 1 mg: 2.8 kg lost against 0.8 kg on placebo; missed significance (p = 0.10) |
| Phase 2b OPTIONS, oral13 | 536 adults enrolled (502 randomized), BMI 30 to 45, on a diet and exercise plan | 24 weeks | Weight loss at 12 weeks | Under 1 kg more than placebo at every dose; primary goal not met |
The doses in these trials were capsules and tablets taken by mouth. They describe the research, not an amount to copy.
Did AOD-9604 cause weight loss in the 12-week trial?
A little, at one dose, and not by the trial's own main test. 283 adults with an average BMI of 42 started treatment on 0, 1, 5, 10, 20 or 30 mg a day, with general diet and exercise advice2. The 1 mg group lost 2.8 kg in 12 weeks and the placebo group 0.8 kg, a 2.0 kg gap. The other doses lost between 1.0 and 2.2 kg, so more drug did not mean more loss2.
The main analysis compared weight at week 0 and week 12. For 1 mg it gave p = 0.10, short of the 0.05 that counts as statistically significant (unlikely to be chance)23. A second analysis that used every fortnightly weigh-in found the rate of loss at 1 mg significant (p < 0.0001), and the company called the trial a success in December 20042. In 2007 it described the response as "bimodal" in men and women alike (some people responded, many did not) and said the 1 mg result reached significance in the women alone3.
These numbers come from the company's own announcements to the Australian stock exchange. The full efficacy results were never published in a peer-reviewed journal: the company's 2014 paper lists them as a manuscript in preparation, and a 2026 review notes that conclusions on AOD-9604's effect rest on sponsor-reported results45.
Why did the 24-week trial fail?
Because the drug added almost nothing on top of a working diet. OPTIONS was built to confirm the 1 mg result under conditions close to a final trial: 536 adults enrolled across 16 sites, doses of 0.25, 0.5 and 1 mg, and a dietitian-supervised diet and exercise programme for everyone3. It was sized to detect a 1.8 kg difference. After both 12 and 24 weeks, weight loss beyond placebo was under 1 kg in every dose group3.
The placebo group lost a lot of weight on the programme alone, and the company concluded the drug "does not combine or synergise" with a successful diet3. One pre-planned subgroup, 149 women who had lost less than 2 kg in the 4-week run-in, showed effects similar to the earlier trial3. A subgroup is one slice of the trial, and a result found in one slice is a lead for a new trial, not proof for everyone. Metabolic ended its obesity programme on 21 February 20073.
Is AOD-9604 safe in people?
In the trials, side effects were as common on AOD-9604 as on placebo. In the 24-week trial 78.7% of people reported at least one side effect, with 83.2% on placebo and 75.6% on the lowest dose; headache and colds led the list1. IGF-1 did not change at 12 or 24 weeks, glucose tolerance tests showed no harm, and no one tested made antibodies against the peptide1.
Two caveats come with that record. The safety summary was written by the company's consultant with two company-linked authors, and Metabolic funded all six trials1. And none of the trials studied injections under the skin, so their safety data cover pills and IV drips, not the daily shots people use now. In the 12-week trial, five people on AOD-9604 had a serious adverse event: four cancers, three of them skin cancers, and one benign fatty lump. The investigator judged none related to the drug1.
Commonly reported: many users notice little; some describe slow fat loss when the peptide is paired with a diet and training; mild redness where the shot went in is the usual complaint.
When to get help Redness that keeps spreading, swelling that grows, or a fever after an injection is a reason to see a doctor the same day.
Is AOD-9604 approved by the FDA?
No. As of November 2026, no major regulator has approved AOD-9604 as a medicine for any use5. On FDA's compounding page (last updated April 22, 2026), AOD-9604 is listed among substances that were in category 2, the group FDA flags as possibly posing significant safety risks, before their nomination was withdrawn13. FDA's 503A categories list (updated May 14, 2026) no longer names it in any category14. FDA's listed concerns are immune reactions for some routes of use, peptide impurities, too little safety information, and serious adverse events possibly linked to it, with the cause unclear13.
The 2013 safety paper adds that an expert panel judged AOD-9604 "generally recognized as safe" (GRAS) for use in foods1. That is a panel's view on food use, not an FDA approval of a medicine. Our legal status page tracks the rules country by country.
What does this mean if you want to lose fat?
The best human evidence says AOD-9604 adds little or nothing to a diet that is already working. The strongest signal was 2.0 kg over placebo at one dose in one 12-week trial, a result the larger trial did not repeat23. Our weight-loss page sets out the options with stronger human trials behind them. If you track a course anyway, record each dose and weigh in on the same day each week, so you see what the scale does rather than what you hope it does.
PepVault logs every dose with its date and time, and its Body page charts each weigh-in, so a twelve-week course and your weight sit side by side in one app. Log it in PepVault
Sources
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. jofem.org
- Metabolic Pharmaceuticals. AOD9604 Phase 2b clinical trial successful (ASX announcement with appendix). 13 December 2004. Archived copy. web.archive.org
- Metabolic Pharmaceuticals. Metabolic's obesity drug: Phase 2B clinical trial results (ASX announcement with appendix). 21 February 2007. Archived copy. web.archive.org
- Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. jofem.org
- Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026. PubMed 42395176
- Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994. PubMed 7987248
- Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. PubMed 11146367
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. PubMed 11673763
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. PubMed 11713213
- Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015. PubMed 26275694
- Cox HD et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015. PubMed 25208511
- UniProt P01241. Somatotropin (human growth hormone), Homo sapiens. uniprot.org
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act: categories 1, 2 and 3 (updated May 14, 2026). fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.